LY2886721 100 mg | 99.94%
TargetMol

LY2886721, a BACE inhibitor, is used for the therapy of Alzheimer’s Disease.
More Information Supplier PageLY2886721, a BACE inhibitor, is used for the therapy of Alzheimer’s Disease.
More Information Supplier PageSLV-2436 (SEL201-88) is a novel effective and ATP-competitive inhibitor of MNK1 and MNK2 (IC50: 10.8/5.4 nM).
More Information Supplier PageSLV-2436 (SEL201-88) is a novel effective and ATP-competitive inhibitor of MNK1 and MNK2 (IC50: 10.8/5.4 nM).
More Information Supplier PageYC-1 is an nitric oxide (NO)-independent activator of soluble guanylyl cyclase(sGC) and an inhibitor of Hypoxia-inducible factor-1alpha (HIF-1alpha).
More Information Supplier PageYC-1 is an nitric oxide (NO)-independent activator of soluble guanylyl cyclase(sGC) and an inhibitor of Hypoxia-inducible factor-1alpha (HIF-1alpha).
More Information Supplier PageYC-1 is an nitric oxide (NO)-independent activator of soluble guanylyl cyclase(sGC) and an inhibitor of Hypoxia-inducible factor-1alpha (HIF-1alpha).
More Information Supplier PageYC-1 is an nitric oxide (NO)-independent activator of soluble guanylyl cyclase(sGC) and an inhibitor of Hypoxia-inducible factor-1alpha (HIF-1alpha).
More Information Supplier PageYC-1 is an nitric oxide (NO)-independent activator of soluble guanylyl cyclase(sGC) and an inhibitor of Hypoxia-inducible factor-1alpha (HIF-1alpha).
More Information Supplier PageTropifexor is a novel and highly potent agonist of FXR with an EC50 of 0.2 nM.
More Information Supplier PageTropifexor is a novel and highly potent agonist of FXR with an EC50 of 0.2 nM.
More Information Supplier Page